Abstract Nucleoporin 98 (NUP98) fusion oncoproteins are observed in a spectrum of
hematologic malignancies, particularly pediatric leukemias with poor patient outcomes …

NUP98 fusion oncoproteins (FO) are drivers in pediatric leukemias and many transform
hematopoietic cells. Most NUP98 FOs harbor an intrinsically disordered region from NUP98 …

Allogeneic hematopoietic stem cell transplantation (HSCT) offers potentially curative
treatment for many children with high-risk or relapsed acute leukemia (AL), thanks to the …

Identification of fusion genes in clinical routine is mostly based on cytogenetics and targeted
molecular genetics, such as metaphase karyotyping, fluorescence in situ hybridization and …

Pediatric acute myeloid leukemia (AML) is a rare, heterogeneous disease, characterized by
recurrent cytogenetic and molecular aberrations. 1, 2 Genetic aberrations are the most …

Acute myeloid leukemia (AML) with co-occurring NUP98-NSD1 and FLT3-ITD is associated
with unfavorable prognosis and represents a particularly challenging treatment group. To …

Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and
transcriptional etiology mainly presenting somatic and germline abnormalities. AML …

Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to
the discovery of somatic mutations with prognostic implications. Although gene-expression …

Over the last two decades, there have been extensive efforts to develop small-molecule
inhibitors of protein–protein interactions (PPIs) as novel therapeutics for cancer, including …

Acute myeloid leukemia (AML) is a clinically, morphologically, and genetically
heterogeneous disorder. Like many malignancies, the genomic landscape of pediatric AML …